MetLife, Inc.
NYSE:METInsurance - Life
-$0.15 today
- Market cap
- $62.71B
- Beta
- 0.78
- P/E (TTM)
- 15.4
- EPS (TTM)
- $5.55
- Dividend yield
- 2.68%
Volume 4.27M
Average 3.49M
MET Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
MetLife, Inc.NYSE: MET
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity broadly unchanged from a year ago
Total equity stood at $27.96B at the end of Q2 FY2026, up 0.1% from a year earlier and up 0.6% from the prior quarter. Over 3 fiscal years it compounded at -1.4% a year.
Context
- Total equity amounted to 3.7% of total assets at the end of Q2 FY2026, down 0.3 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +0.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 28.92B USD
- Year-over-year change
- +4.4%
- 4-year CAGR
- -19.2%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.92B | +4.4% |
| FY2024 | 2024-12-31 | 27.7B | -8.4% |
| FY2023 | 2023-12-31 | 30.25B | +0.4% |
| FY2022 | 2022-12-31 | 30.13B | -55.5% |
| FY2021 | 2021-12-31 | 67.75B | — |
Total Equity vs competitors
How MET compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +0.1% is the 8th highest of 11, against a peer median of +4.9%.
- Total equity amounts to 3.7% of total assets for MET, versus a peer median of 5.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | CA$54.93B CAD | +7.2% | +2.7% | 5.0% | |
| Jun 2026 | $31.94B USD | -3.6% | +27.4% | 4.1% | |
| Jun 2026 | $30.31B USD | +11.4% | +13.6% | 26.1% | |
| Jun 2026 | $27.96B USD | +0.1% | -1.4% | 3.7% | |
| Jun 2026 | $11.35B USD | +18.9% | +28.8% | 2.6% | |
| Jun 2026 | $10.81B USD | -4.5% | +8.4% | 17.0% | |
| Jun 2026 | $6.64B USD | +1.4% | +12.1% | 3.6% | |
| Jun 2026 | $6.16B USD | +13.6% | +14.8% | 19.5% | |
| Sep 2026 | $5.08B USD | -21.0% | +6.9% | 2.1% | |
| Sep 2026 | $2.83B USD | +23.1% | +6.4% | 19.5% | |
| Jun 2026 | $2.59B USD | +2.7% | +14.3% | 6.5% | |
| Peer median (excluding MET) | — | +4.9% | +12.8% | 5.8% | |
Competitors are the stored peer set for MET. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 20.05B | 20.2B | 20.64B | 20.07B | 22.03B |
| Short-term Investments | 347.45B | 293.13B | 296.19B | 88.71B | 103.31B |
| Net Receivables | 20.52B | 22.17B | 33.78B | 34.26B | 54.25B |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 388.02B | 335.49B | 350.62B | 143.04B | 179.59B |
| Property, Plant & Equipment (Net) | 0 | 1.93B | 1.99B | 1.85B | 1.7B |
| Goodwill | 9.54B | 9.3B | 9.24B | 8.9B | 9.61B |
| Intangible Assets | 16.06B | 19.65B | 20.15B | 19.63B | 21.11B |
| Long-term Investments | 147.37B | 134.83B | 144.19B | 346.67B | 362.81B |
| Tax Assets | 189M | 2.44B | 2.61B | 2.99B | 2.59B |
| Other Non-current Assets | 198.54B | 159.44B | 158.79B | 154.38B | 167.77B |
| Total Non-current Assets | 371.69B | 327.58B | 336.97B | 534.42B | 565.58B |
| Total Assets | 759.71B | 663.07B | 687.58B | 677.46B | 745.17B |
| Account Payables | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 341M | 175M | 119M | 465M | 1.56B |
| Tax Payables | 0 | 42M | 190M | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 230.92B | 229.97B | 239.93B | 240.48B | 257.46B |
| Total Current Liabilities | 263.18B | 251.08B | 257.58B | 258.07B | 276.14B |
| Long-term Debt | 17.09B | 17.75B | 18.68B | 18.24B | 18.62B |
| Deferred Tax Liabilities | 9.69B | 950M | 927M | 132M | 536M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 402B | 363.11B | 380.12B | 373.3B | 420.95B |
| Total Non-current Liabilities | 428.78B | 381.86B | 399.76B | 391.69B | 440.11B |
| Total Liabilities | 691.96B | 632.95B | 657.33B | 649.75B | 716.25B |
| Common Stock | 12M | 12M | 12M | 12M | 12M |
| Retained Earnings | 41.2B | 40.33B | 40.15B | 42.63B | 44.29B |
| Accumulated OCI | 10.92B | (22.62B) | (19.24B) | (21.19B) | (18.08B) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 267M | 244M | 238M | 258M | 523M |
| Total Equity | 67.75B | 30.13B | 30.25B | 27.7B | 28.92B |
| Total Debt | 17.43B | 17.98B | 18.83B | 18.72B | 20.18B |
| Net Debt | (2.62B) | (2.22B) | (1.81B) | (1.35B) | (1.85B) |
MetLife, Inc.
NYSE:MET
Intrinsic Alpha fair value
Locked
Current Price
$99.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.